An evidence-based review of therapies for canine chronic kidney disease

Journal of Small Animal Practice

Volumn 51, Issue 5, 2010, Pages 244-252

  Roudebush, P ^a   Polzin, D J ^b   Adams, L G ^c   Towell, T L ^a   Forrester, S D ^a  

^a Hill's Pet Nutrition Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CALCITRIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; OMEGA 3 FATTY ACID;

ANIMAL; ANIMAL DISEASE; ANIMAL FOOD; CHRONIC KIDNEY FAILURE; DIET THERAPY; DOG; DOG DISEASE; EVIDENCE BASED PRACTICE; FLUID THERAPY; REVIEW; DOG DISEASES; KIDNEY FAILURE, CHRONIC; VETERINARY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL FEED; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CALCITRIOL; DOG DISEASES; DOGS; ERYTHROPOIETIN; EVIDENCE-BASED PRACTICE; FATTY ACIDS, OMEGA-3; FLUID THERAPY; KIDNEY FAILURE, CHRONIC;

CANIS FAMILIARIS;

EID: 77952702386     PISSN: 00224510     EISSN: 17485827     Source Type: Journal    
DOI: 10.1111/j.1748-5827.2010.00932.x     Document Type: Review

References (65)

1. Acierno M J. Systemic hypertension in renal disease. Current Veterinary Therapy XIV 2009, 910-913. Bonagura J DTwedt D C. In, Eds, Elsevier Science, Philadelphia PA, USA, pp
2. Adams L G. Chronic renal failure. The 5-Minute Veterinary Consult 2004, 1124-1125. Tilley L PSmith F W K. In, 4th edn., Eds, Lippincott William & Wilkins, Philadelphia PA, USA, pp
3. Allen T A, Polzin D J, Adams L G. Renal disease. Small Animal Clinical Nutrition 2000, 563-598. Hand M S, Roudebush P, In, 4th edn, Eds, C. D. Thatcher, R. L. Remillard, and, Mark Morris Institute, Topeka KS, USA, pp
4. Anderson S, Rennke H G, Brenner B M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rats. Journal of Clinical Investigation 1986, 77:1993-2000.
5. Barsanti J A, Finco D R. Dietary management of chronic renal failure in dogs. Journal of the American Animal Hospital Association 1985, 21:371-376.
6. Block G A, Hulbert-Shearon T E, Levin N W, Port F K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Disease 1998, 31:607-617.
7. Bovee K C. Medical management of chronic renal failure: control of hyperphosphatemia: Current Veterinary Therapy VII. 1980, 1103-1104. Kirk R W. In, Ed, W. B. Saunders, Philadelphia PA, USA, pp
8. Brody T. Nutritional Biochemistry. 1999, 575. 2nd edn, Academic Press, San Diego CA, USA, p
9. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, Egner B, Elliott J, Henik R, Labato M, Littman M, Polzin D, Ross L, Snyder P, Stenpien R. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine 2007, 21:542-558.
10. Brown S A. Evaluation of chronic renal disease: a staged approach. Compendium on Continuing Education for the Practicing Veterinarian 1999, 21:752-763.
11. Brown S A. Pathophysiology of systemic hypertension: Textbook of Veterinary Internal Medicine. 2005, 472-476. Ettinger S JFeldman E C. In:, 6th edn., Eds, W. B. Saunders, Philadelphia PA, USA, pp
12. Brown S A. Oxidative stress and chronic kidney disease. Veterinary Clinics of North America Small Animal Practice 2008, 38:157-166.
13. Brown S A, Brown C A, Crowell W A, Barsanti J A, Allen T, Cowell C, Finco D R. Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. Journal of Laboratory Clinical Medicine 1998, 5:447-455.
14. Brown S A, Crowell W A, Barsanti J A, White J V, Finco D R. Beneficial effects of dietary mineral restriction in dogs with marked reduction of functional renal mass. Journal of the American Society of Nephrology 1991, 1:1169-1179.
15. Brown S A, Finco D R, Brown C A, Crowell W A, Alva R, Ericcson G E, Cooper T. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. American Journal of Veterinary Research 2003, 64:321-327.
16. Brown S A, Walton C L, Crawford P, Bakris G L. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney International 1993, 43:1210-1218.
17. Casas J P, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani A D, MacAllister R J. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
18. Chew D J, Nagode L A. Calcitriol in treatment of chronic renal failure. Current Veterinary Therapy XI 1992, 857-860. Kirk R W, Bonagura J D. In, Eds, W. B. Saunders, Philadelphia PA, USA, pp
19. Cockcroft P D, Holmes M A. Handbook of Evidence-Based Veterinary Medicine 2003, Blackwell Publishing, Oxford, UK
20. Cowgill L D. Anemia of chronic renal failure. The 5-Minute Veterinary Consult 2004, 75. Tilley L PSmith F W K. In, 4th edn, Eds, Lippincott William & Wilkins, Philadelphia PA, USA, p
21. Cowgill L D. Erythropoietin-replacement therapy. 2009, http://www.acvim.org, Personal communication on American College of Veterinary Internal Medicine listserve, accessed 01 September 2009
22. Cowgill L D, Francey T. New directions for the medical management of renal disease. 2004, Proceedings of the Hill's European Symposium on Chronic Renal Disease, Rhodes, Greece. pp 40-47
23. Cowgill L D, James K M, Levy J K, Browne J K, Miller A, Lobingier R T, Egrie J C. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. Journal of the American Veterinary Medical Association 1998, 212:521-528.
24. DiBartola S P, Willard M D. Disorders of phosphorus: hypophosphatemia and hyperphosphatemia. Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice 2006, 195-209. DiBartola S P, In, 3rd edn, Ed, Elsevier Science, St Louis MO, USA, pp
25. Elliott D A, Riel D L, Rogers Q R. Complications and outcomes associated with use of gastrostomy tubes for nutritional management of dogs with renal failure: 56 cases (1994-1999). Journal of the American Veterinary Medical Association 2000, 217:1337-1342.
26. Finco D R, Brown S A, Crowell W A, Duncan R J, Barsanti J A, Bennett S E. Effects of dietary phosphorus and protein in dogs with chronic renal failure. American Journal of Veterinary Research 1992a, 53:2264-2271.
27. Finco D R, Brown S A, Crowell W A, Groves C A, Duncan J R, Barsanti J A. Effects of phosphorus/calcium-restricted and phosphorus/calcium-replete 32% protein diets in dogs with chronic renal failure. American Journal of Veterinary Research 1992b, 53:157-163.
28. Finco D R, Crowell W A, Barsanti J A. Effects of three diets on dogs with induced chronic renal failure. American Journal of Veterinary Research 1985, 46:646-653.
29. Gerber B, Hässig M, Reusch C E. Serum concentrations of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol in clinically normal dogs and dogs with acute and chronic renal failure. American Journal of Veterinary Research 2003, 64:1161-1166.
30. Geyman J P. Evidence-based medicine in primary care: an overview. Evidence-Based Clinical Practice: Concepts and Approaches 2000, 1-11. Geyman J PDeyo R ARamsey S D. In, Eds, Butterworth-Heinemann, Boston MA, USA, pp
31. Grauer G F, Greco D S, Getzy D M, Cowgill L D, Vaden S L, Chew D J, Polzin D J, Barsanti J A. Effects of enalapril treatment versus placebo as a treatment for canine idiopathic glomerulonephritis. Journal of Veterinary Internal Medicine 2000, 14:526-533.
32. Grodecki K M, Gains M J, Baumal R, Osmond D H, Cotter B, Valli V E, Jacobs R M. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. Journal of Comparative Pathology 1997, 117:209-225.
33. Henik R A. Systemic hypertension and its management. Veterinary Clinics of North America:Small Animal Practice 1997, 27:1355-1372.
34. 2009, http://www.iris-kidney.com, International Renal Interest Society, accessed 20 May 2009
35. Jacob F, Osborne C, Polzin D, Neaton J, Kirk C, Allen T, Swanson L. Effect of dietary modification on health-related quality of life (HRQL) in dogs with spontaneous chronic renal failure. 2004, Proceedings of the 22nd ACVIM Forum. Minneapolis MN, USA. p 828
36. Jacob F, Polzin D J, Osborne C A, Allen T A, Kirk C A, Neaton J D, Lekcharoensuk C, Swanson L L. Clinical evaluation of dietary modification for treatment of spontaneous chronic renal failure in dogs. Journal of the American Veterinary Medical Association 2002, 220:1163-1170.
37. Jacob F, Polzin D J, Osborne C A, Neaton J D, Kirk C A, Allen T A, Swanson L L. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. Journal of the American Veterinary Medical Association 2005, 226:393-400.
38. Jacob F, Polzin D J, Osborne C A, Neaton J D, Lekcharoensuk C, Allen T A, Kirk C A, Swanson L L. Association between initial systolic blood pressure and risk of developing a uremic crisis or of dying in dogs with chronic renal failure. Journal of the American Veterinary Medical Association 2003, 222:322-329.
39. Jafar T H, Schmid C H, Landa M, Maschio G, Marcantoni C, de Jong P E, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Annals of Internal Medicine 2001, 135:73-87.
40. Keene B W. Towards evidence-based veterinary medicine. Journal of Veterinary Internal Medicine 2000, 14:118-119.
41. Lees G E, Scott S A, Elliott J, Grauer G F, Vaden S L. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum consensus statement (small animal). Journal of Veterinary Internal Medicine 2005, 19:377-385.
42. Littman M P. Hypertension. In: Textbook of Veterinary Internal Medicine. 2000, 179-182. Ettinger S JFeldman E C. 5th edn, Eds, W. B. Saunders, Philadelphia PA, USA, pp
43. Marr C M. Defining the clinically relevant questions that lead to the best evidence: what is evidence-based medicine. Equine Veterinary Journal 2003, 35:333-336.
44. Mitch W E. Mechanisms causing loss of lean body mass in kidney disease. American Journal of Clinical Nutrition 1998, 67:359-366.
45. Moriello K A. Introducing evidence based clinical reviews in Veterinary Dermatology. Veterinary Dermatology 2003, 14:119-120.
46. Morris M L. Phosphorus: the deadly element in renal failure: Proceedings of the 47th Annual American Animal Hospital Association Meeting. 1980, 171-172. Los Angeles CA, USA, pp
47. Nagode L A, Chew D J. Nephrocalcinosis caused by hyperparathyroidism in progression of renal failure: treatment with calcitriol. Seminars in Veterinary Medicine and Surgery (Small Animal) 1992, 7:202-220.
48. Nagode L A, Chew D J. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Veterinary Clinics of North America: Small Animal Practice 1996, 26:1293-1330.
49. Polzin D J. Importance of clinical trials in evaluating therapy of renal diseases. Veterinary Clinics of North America: Small Animal Practice. 1996, 26:1519-1525.
50. Polzin D J. 11 guidelines for conservatively treating chronic kidney disease Veterinary Medicine. 2007, 102:788-799.
51. Polzin D J, Lund E, Walter P, Klausner J. From journal to patient: evidence-based medicine. Current Veterinary Therapy XIII 2000, 2-8. Kirk R W, Bonagura J D, In:, Eds, W. B. Saunders, Philadelphia PA, USA, pp
52. Polzin D J, Osborne C A, Ross S. Chronic kidney disease. Textbook of Veterinary Internal Medicine 2005a, 1756-1785. Ettinger S J, Feldman E C, In:, 6th edn, Eds, W. B. Saunders, Philadelphia PA, USA, pp
53. Polzin D, Ross S, Osborne C, Lulich J, Swanson L. Clinical benefit of calcitriol in canine chronic kidney disease. Journal of Veterinary Internal Medicine 2005b, 19:-433.
54. Randolph J E, Scarlett J, Stokol T, MacLeod J N. Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. Journal of Veterinary Internal Medicine 2004, 18:81-91.
55. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Seminars in Nephrology 2006, 26:283-289.
56. Roudebush P, Allen T A, Dodd C E, Novotny B J. Application of evidence-based medicine to veterinary clinical nutrition. Journal of the American Veterinary Medical Association 2004, 224:1766-1771.
57. Roudebush P, Polzin D J, Ross S J, Towell T L, Adams L G, Forrester S D. Therapies for feline chronic kidney disease. What is the evidence? Journal of Feline Medicine & Surgery 2009, 11:195-210.
58. Sackett D L, Straus S E, Richardson W S. Introduction. In: Evidence-Based Medicine: How to Practice and Teach EBM. 2000, 1-12. Sackett D L, Straus S E, Richardson W S. 2nd edn, Eds, Churchill-Livingstone, Philadelphia, PA, USA, pp
59. Schulman R L, Krawiec D R. Gastrointestinal complications of uremia: Current Veterinary Therapy XIII. 2000, 864-865. Kirk R W, Bonagura J D. In, Eds, W. B. Saunders, Philadelphia PA, USA, pp
60. Tabaru H, Finco D R, Brown S A, Cooper T. Influence of hydration state on renal functions of dogs. American Journal of Veterinary Research 1993, 54:1758-1764.
61. Tenhündfeld J, Wefstaedt P, Nolte I J A. A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs. Journal of the American Veterinary Medical Association 2009, 234:1031-1037.
62. Wehner A, Harmann K, Hirschberger J. Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases. Veterinary Record 2008, 162:141-147.
63. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular schlerosis. Kidney International 1989, 35:654-660.
64. Yu S, Gross K L, Allen T A. A renal food supplemented with vitamins E, C and beta-carotene reduces oxidative stress and improves kidney function in client-owned dogs with stages 2 or 3 kidney disease. Journal of Veterinary Internal Medicine 2006, 20:1537.
65. Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. American Journal of Medical Science 2000, 320:100-106.